ReviewCancers2024
Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Clinical and translational roles of circulating tumor cells in non-small cell and small cell lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA.Scientific reports · 2026Article
- Combination Therapy Using Heat-KilledIranian journal of biotechnology · 2025Article
- Tumor Necrosis Factor-Alpha's Role in the Pathophysiology of Colon Cancer.Diseases (Basel, Switzerland) · 2025Review
- Prognostic Value of the Number of Circulating Tumor Cells in Patients with Metastatic Non-Small Cell Lung Cancer.Micromachines · 2025Article
- Review
- Unveiling the dual role of circulating tumor cells in colorectal cancer immunotherapy: a comprehensive review of biomarker utility and immune microenvironment crosstalk.Frontiers in immunology · 2025Review
- A retrospective analysis of key predictors and patient outcomes: Using artificial intelligence for precision survival prediction in colorectal cancer.German medical science : GMS e-journal · 2025Article
- Colorectal Cancer in Elderly Patients: Insights into Presentations, Prognosis, and Patient Outcomes.Medicina (Kaunas, Lithuania) · 2024Observational
- Diagnosis of Relapse of Colorectal Adenocarcinoma through CEA Fluctuation.Reports (MDPI) · 2024Article
- A management of patients achieving clinical complete response after neoadjuvant therapy and perspectives: on locally advanced rectal cancer.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The ability to predict or detect colorectal cancer (CRC) recurrence early after surgery enables physicians to apply appropriate treatment plans and different follow-up strategies to improve patient survival. Overall, 30-50% of CRC patients experience cancer recurrence after radical surgery, but current surveillance tools have limitations in the precise and early detection of cancer recurrence. Circulating tumor cells (CTCs) are cancer cells that detach from the primary tumor and enter the bloodstream. These can provide real-time information on disease status. CTCs might become novel markers for predicting CRC recurrence and, more importantly, for making decisions about additional adjuvant chemotherapy. In this review, the clinical application of CTCs as a therapeutic marker for stage II CRC is described. It then discusses the utility of CTCs for monitoring cancer recurrence in advanced rectal cancer patients who undergo neoadjuvant chemoradiotherapy. Finally, it discusses the roles of CTC subtypes and CTCs combined with clinicopathological factors in establishing a multimarker model for predicting CRC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.